AstraZeneca quarterly net profit slumps

British pharmaceuticals giant AstraZeneca on Thursday said third-quarter net profits tumbled by about a third as a large exceptional gain was not repeated. Earnings after taxation dived 32 percent to $686 million (592 million euros) in the three months to September 30, AstraZeneca said in a results statement.

That compared with net profit of $1.01 billion for the same part of the previous year, when the group had enjoyed a large one-off tax gain. AstraZeneca was boosted in 2016 by an exceptional tax benefit of $453 million following agreements on transfer pricing arrangements with British, Canadian and Swedish tax authorities for the period 2004-2016.

Total revenues meanwhile rose nine percent to $6.2 billion in the third quarter of 2017, buoyed by a multi-billion-dollar deal unveiled in July to jointly develop key cancer drugs with Merck. However, AstraZeneca’s product sales fell three percent to $4.8 billion, hit by generic competition for blockbuster cholesterol-lowering drug Crestor in the key United States market.

Get this and more in your mailbox. Enter your email address:

Do you ever witness anything interesting or exciting? Just take out your phone and send us the exclusive pictures or video and we will pay you cash. E-mail to Please include location, date, involved persons or why it is important and other details.

Leave a Reply